Literature DB >> 3734130

The application of stable isotopes to studies of drug bioavailability and bioequivalence.

R L Wolen.   

Abstract

The increased availability of chemical intermediates and automated instrumentation has resulted in expanded use of stable isotopes for bioavailability and bioequivalence studies in recent years. Initially, stable isotopes were confined to the labeling of mass internal standard compounds for gas chromatography/mass spectrometry. More recently, their in vivo use has expanded and proved to be a powerful pharmacologic tool. The lack of toxicity of stable isotopes, particularly deuterium and carbon-13, make them ideally suited for human studies. The primary advantage of the isotopic methods is that the drug can be administered concomitantly either by two routes (e.g., parenteral and oral) or in two formulations (e.g., solution and solid dosage). Thus, a single set of blood samples serves to describe the time course of the routes or formulations being compared. The concomitant administration reduces variability inherent in dual administration, the single assay for both forms further reduces variation, and the method minimizes both drug exposure and discomfort to the subject. In addition to single-dose administration, in which two routes or dosage forms are compared, the technique is well suited to "pulse" administration, wherein the kinetics of a single dose, during multiple or chronic dosing regimens, can be compared with single-dose kinetics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734130     DOI: 10.1002/j.1552-4604.1986.tb03551.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

1.  Summary workshop report: Facilitating oral product development and reducing regulatory burden through novel approaches to assess bioavailability/bioequivalence.

Authors:  James E Polli; Jack A Cook; Barbara M Davit; Paul A Dickinson; Domenick Argenti; Nancy Barbour; Alfredo García-Arieta; Jean-Marie Geoffroy; Kerry Hartauer; Shoufeng Li; Amitava Mitra; Francis X Muller; Vivek Purohit; Manuel Sanchez-Felix; John W Skoug; Kin Tang
Journal:  AAPS J       Date:  2012-06-09       Impact factor: 4.009

Review 2.  Assessing the bioequivalence of analogues of endogenous substances ('endogenous drugs'): considerations to optimize study design.

Authors:  Sanjeeva Dissanayake
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 3.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 4.  Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages.

Authors:  T R Browne
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

5.  Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.

Authors:  M O Karlsson; U Bredberg
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

Review 6.  Deuterated drugs: where are we now?

Authors:  Graham S Timmins
Journal:  Expert Opin Ther Pat       Date:  2014-07-29       Impact factor: 6.674

7.  Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study.

Authors:  P A Soons; A G de Boer; P van Brummelen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

8.  Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.

Authors:  S L Preston; G L Drusano; P Glue; J Nash; S K Gupta; P McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

9.  Estimation of bioavailability on a single occasion after semisimultaneous drug administration.

Authors:  M O Karlsson; U Bredberg
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

10.  Bioavailability of flumequine after semisimultaneous administration to veal calves.

Authors:  B A Meijer; K G Ceyssens; W T de Jong; B I de Grève
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.